Exelixis (EXEL)
(Delayed Data from NSDQ)
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Zacks News
Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit
by Zacks Equity Research
Emergent BioSolutions Inc. (EBS) announced that it has inked an agreement to acquire the FDA-licensed smallpox vaccine's business of Sanofi (SNY) in an all-cash deal of up to $125 million.
Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?
by Zacks Equity Research
Shares of Exelixis, Inc. (KITE) have gained almost 4.68% on Aug 12. The company's shares have rallied a whopping 77% this year so far, outperforming the 7.8% increase registered by the Zacks categorized industry during this period.
BioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) announced an exclusive partnership agreement with Purdue Pharma, a Canadian pharmaceutical company, for commercializing its pain drug Belbuca in Canada.
Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform
by Zacks Equity Research
We issued an updated research report Endocyte, Inc. (ECYT) on Jul 12.
Why Exelixis (EXEL) Could Be an Impressive Growth Stock
by Zacks Equity Research
Exelixis (EXEL) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Arena Announces Secondary Stock Offering of 150M Shares
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) plans to offer and sell 150 million shares of its common stock, subject to customary closing conditions.
Five Scorching Hot Stocks Screaming Higher
by David Bartosiak
Five Zacks Rank #1 (Strong Buy) stocks at 52-week highs pushing even higher
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx
by Zacks Equity Research
Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC.
The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners
Best Stocks For The Second Half of 2017
by Brian Bolan
A look at some stocks that are expected to show some good growth in the back half of the year.
AVEO's Kidney Cancer Candidate Gets CHMP Recommendation
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).
Cara Therapeutics (CARA) Shows Strength: Stock Adds 12.2 % in Session
by Zacks Equity Research
Cara Therapeutics, Inc. (CARA) was a big mover last session, as the company saw its shares rise over 12% on the day
Top Ranked Momentum Stocks to Buy for June 27th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 27th:
AVEO Reaches Enrollment Target in Pivotal Tivozanib Study
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) announced that the phase III study, TIVO-3, evaluating tivozanib in patients with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target
Exelixis's Cabometyx Positive for First-Line Kidney Cancer
by Zacks Equity Research
Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.
Exelixis Initiates Cabozantinib-Tecentriq Combination Trial
by Zacks Equity Research
Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche's (RHHBY) Tecentriq.
Pfizer's Kidney Cancer Drug Gets Acceptance in the U.S. & EU
by Zacks Equity Research
Pfizer Inc. (PFE) announced encouraging news with the FDA and the European Medicines Agency (EMA) accepting the company's regulatory submission for label expansion of its cancer drug, Sutent (sunitinib).
Why Is Exelixis (EXEL) Down 20.9% Since the Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights: Sonus Networks, CNH Industrial, WellCare Health Plans, Exelixis and Best Buy
by Zacks Equity Research
Zacks.com featured highlights: Sonus Networks, CNH Industrial, WellCare Health Plans, Exelixis and Best Buy
Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus
by Zacks Equity Research
Exelixis posted earnings in the first quarter of 2017 while revenues beat estimates driven by Cabometyx.
Play Potential Earnings Beat with These 5 Top-Ranked Stocks
by Zacks Equity Research
Bet on these top-ranked stocks that have the potential to beat the earnings estimate.
Is Intercept (ICPT) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Is Intercept (ICPT) Poised for a Beat this Earnings Season?
Apple (AAPL) to Report Q2 Earnings: Is a Beat in Store?
by Zacks Equity Research
Apple, Inc. (AAPL) is set to report its second-quarter fiscal 2017 results on May 2.
What to Expect from Quotient Technology (QUOT) Q1 Earnings?
by Zacks Equity Research
Quotient Technology Inc. (QUOT) is set to report first-quarter 2017 results on May 2.
Insperity (NSP) Q1 Earnings: Is a Surprise in the Cards?
by Zacks Equity Research
Insperity, Inc. (NSP) is set to report first-quarter 2017 results on May 1.